{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:48:08Z","timestamp":1787647688467,"version":"build-2736575974"},"reference-count":55,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015297","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T10:45:26Z","timestamp":1719485126000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer"],"prefix":"10.1002","volume":"2024","author":[{"given":"Christina","family":"Pappa","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology Division; Oxford University Hospitals; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadra","family":"Galaal","sequence":"additional","affiliation":[{"name":"Surgical Oncology Department; Sultan Qaboos Comprehensive Cancer Centre SQCCCRC; Muscat Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Smyth","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology Division; Oxford University Hospitals; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E","family":"Bristow","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology; University of California - Irvine, Medical Center; Orange CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S","family":"Khashan","sequence":"additional","affiliation":[{"name":"School of Public Health; University College Cork; Cork Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo'iad","family":"Alazzam","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology Division; Oxford University Hospitals; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"10.1002\/14651858.CD015297-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD015297-BIB0002|cit2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008765.pub2","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015297-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/ijms24031973","article-title":"Predicting prognosis and platinum resistance in ovarian cancer: role of immunohistochemistry biomarkers","volume":"24","author":"Atallah","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1002\/14651858.CD015297-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","article-title":"The systemic treatment of recurrent ovarian cancer revisited","volume":"32","author":"Baert","year":"2021","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015297-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/jco.2001.19.6.1809.","article-title":"Reliability and validity of the functional assessment of cancer therapy - ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"The Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015297-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"International Journal of Gynecology & Obstetrics"},{"issue":"5","key":"10.1002\/14651858.CD015297-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/COC.0000000000000310","article-title":"Secondary surgery versus chemotherapy for recurrent ovarian cancer","volume":"41","author":"Bickell","year":"2018","journal-title":"American Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015297-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the Functional Assessment of Cancer Therapy \u2013 General (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Evaluation & the Health Professions"},{"issue":"5","key":"10.1002\/14651858.CD015297-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/annonc\/mdz104","article-title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","volume":"30","author":"Buechel","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015297-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"I6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD015297-BIB0011|cit11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008273.pub2","article-title":"Information interventions for orienting patients and their carers to cancer care facilities","author":"Chan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD015297-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1055\/a-1128-0280","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"80","author":"Claussen","journal-title":"Geburtshilfe und Frauenheilkunde"},{"issue":"10106","key":"10.1002\/14651858.CD015297-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1002\/14651858.CD015297-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD015297-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015297-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub6","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","author":"Coleridge","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015297-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","article-title":"Ovarian cancer","volume":"60","author":"Colombo","year":"2006","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"5","key":"10.1002\/14651858.CD015297-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","journal-title":"International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society"},{"issue":"8","key":"10.1002\/14651858.CD015297-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41416-022-02108-7","article-title":"INOVATYON\/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin\/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin\/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line","volume":"128","author":"Colombo","year":"2023","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015297-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD015297-BIB0021|cit21","unstructured":"National Cancer Institute Common terminology criteria for adverse events (CTCAE) version 5 National Institutes of Health, US Department of Health and Human Services 2017 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"10.1002\/14651858.CD015297-BIB0022|cit22","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD015297-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD015297-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jamaoncol.2018.2761","article-title":"Defining survivorship trajectories across patients with solid tumors: an evidence-based approach","volume":"4","author":"Dood","year":"2018","journal-title":"JAMA Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015297-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Du Bois","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015297-BIB0026|cit26","unstructured":"EndNote Clarivate 2024"},{"key":"10.1002\/14651858.CD015297-BIB0027|cit27","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD015297-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007930","article-title":"Angiogenesis inhibitors for the treatment of epithelial ovarian cancer","author":"Gaitskell","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015297-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007822","article-title":"Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer","author":"Galaal","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015297-BIB0030|cit30","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"3","key":"10.1002\/14651858.CD015297-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2017.06.007","article-title":"The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery","volume":"146","author":"Grimm","year":"2017","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015297-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"357","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015297-BIB0033|cit33","unstructured":"Higgins JPT Green S Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD015297-BIB0034|cit34","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"7","key":"10.1002\/14651858.CD015297-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1024\/0040-5930.64.7.375","article-title":"Epithelial ovarian cancer","volume":"64","author":"Hilpert","year":"2007","journal-title":"Therapeutische Umschau. Revue th\u00e9rapeutique"},{"issue":"2","key":"10.1002\/14651858.CD015297-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"23","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"issue":"10177","key":"10.1002\/14651858.CD015297-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015297-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015297-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40635-023-00543-1","article-title":"Perioperative advanced haemodynamic monitoring of patients undergoing multivisceral debulking surgery: an observational pilot study","volume":"11","author":"Middel","year":"2023","journal-title":"Intensive Care Medicine Experimental"},{"key":"10.1002\/14651858.CD015297-BIB0040|cit40","unstructured":"National Cancer Institute and End Results Program Cancer Stat Facts: Ovarian Cancer https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"issue":"24","key":"10.1002\/14651858.CD015297-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015297-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"AGO-OVAR 2.21\/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015297-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"25","key":"10.1002\/14651858.CD015297-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015297-BIB0045|cit45","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"2","key":"10.1002\/14651858.CD015297-BIB0046|cit46","first-page":"75","article-title":"Neoadjuvant chemotherapy for elderly patients with advanced stage ovarian carcinoma","volume":"22","author":"Salman","year":"2020","journal-title":"The Israel Medical Association Journal"},{"key":"10.1002\/14651858.CD015297-BIB0047|cit47","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD015297-BIB0048|cit48","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"1","key":"10.1002\/14651858.CD015297-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"10.1002\/14651858.CD015297-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"2","key":"10.1002\/14651858.CD015297-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929.pub4","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","author":"Tattersall","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015297-BIB0052|cit52","unstructured":"US Cancer Statistics Working Group U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. U.S. Cancer Statistics Data Visualizations Tool, based on 2020 submission data (1999-2018) https:\/\/www.cdc.gov\/cancer\/dataviz"},{"issue":"3","key":"10.1002\/14651858.CD015297-BIB0053|cit53","first-page":"227","article-title":"Treatment algorithm in patients with ovarian cancer","volume":"12","author":"Vergote","year":"2020","journal-title":"Facts, Views & Vision in ObGyn"},{"issue":"12","key":"10.1002\/14651858.CD015297-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/00005650-198412000-00005","article-title":"Choosing the correct unit of analysis in medical care experiments","volume":"22","author":"Whiting-O'Keefe","journal-title":"Medical Care"},{"issue":"8","key":"10.1002\/14651858.CD015297-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006119","article-title":"Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment","author":"Zachou","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T10:45:40Z","timestamp":1719485140000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015297"}},"subtitle":[],"editor":[{"name":"Cochrane Z_INACTIVE_Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015297","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}